
With antimicrobial resistance a rising threat, the World Health Organization is working to heighten awareness of the urgent need for new therapies.

With antimicrobial resistance a rising threat, the World Health Organization is working to heighten awareness of the urgent need for new therapies.

Clinicians offer insights on a variety of elements surrounding boosters.

What steps need taken to end viral hepatitis by 2030? “It all comes down to testing,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

Implicating adenovirus for hepatitis of unknown cause in children is confounded by its absence in some cases, and from all tested hepatic tissue.

Viral hepatitis “can and should be managed within primary care,” says Dr. Thomas Robertson.

A patient presented with a history of uncontrolled HIV and a history of polysubstance use.

An HIV-positive woman in her 60s has recovered from a simultaneous heart and kidney transplant.

Here is a review of the literature for this class of antibiotics.

Investigators designed a quasi-experimental pre- and post-intervention analysis comparing a pre-intervention cohort receiving IV drip antibiotic infusion with a post-intervention cohort receiving IVP administration.

Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.

Last weekend, the World Health Organization declared the monkeypox viral outbreaks a Public Health Emergency of the International Concern (PHEIC).

A new study demonstrated that gut organisms can alter drug availability by biotransformation on a significantly broader scale than previously expected.


As the pandemic enters its third year, fatigue and frustration grow, but there is hope for the future.

Working to Fight AMR is working in Washington DC to help pass policies in Congress to help alleviate this significant issue.

Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.

A robust stewardship program requires a comprehensive investment in technology and staff.

This Israeli study found 3 and 4 doses of Pfizer-BioNTech bolstered antibody titers in adults 60 and older.

The CDC is advising clinicians to test for parechovirus in infants exhibiting fever, sepsis-like syndrome, or signs of neurological impairment.

He is experiencing mild symptoms and is going to take Paxlovid.

With the warmer months in full swing, here are clinical considerations and strategies for tick-borne infections.

As monkeypox cases increase, investigators are turning to smallpox antivirals.

This agent is likely best utilized as part of a combination when treating this bacterium but data regarding appropriate combinations are scarce.

This decision follows votes to allow the vaccine to be indicated for prevention of the virus in adults 18 years and older.

2 patients died of Marburg virus in the southern Ashanti region of Ghana. Nearly 100 close contacts are now under observation for the infectious disease, which is a cousin of the Ebola virus.

The BA.2 COVID-19 variant maintained the mutations necessary for viral entry, but developed an increased ability to evade neutralization by monoclonal antibodies.

Though all racial and ethnic groups saw declines in life expectancy, the impact was greater among members of minority groups.

Federal government agencies offer a best practices approach for testing, announce more laboratories are testing for the virus and provide insights on vaccines and therapies.

In children 5-11 years old, 2 doses of the Pfizer-BioNTech COVID-19 vaccine were moderately effective against documented, symptomatic Omicron infection.

Predicted time to breakthrough infection after mRNA vaccination was significantly longer than the time to breakthrough infection after natural infection or after viral vector vaccination.